Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: An open-label, single-sequence, clinical trial

Drugs and Aging

Volumn 26, Issue 9, 2009, Pages 781-790

  Small, David S ^a   Wrishko, Rebecca E ^a   Ernest II, C Steven ^a   Ni, Lan ^a   Winters, Kenneth J ^a   Farid, Nagy A ^a   Li, Ying G ^a   Salazar, Daniel E ^b   Payne, Christopher D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; PRASUGREL; R 138727; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIZZINESS; DRY THROAT; EPISTAXIS; FATIGUE; FEMALE; FLUSHING; GINGIVA BLEEDING; HEADACHE; HUMAN; LACERATION; LETHARGY; LIMB INJURY; MAINTENANCE DRUG DOSE; MALE; METRORRHAGIA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; STEADY STATE; THIRST; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; AGING; ASPIRIN; BLEEDING TIME; BODY MASS INDEX; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRODRUGS; PURINERGIC P2 RECEPTOR ANTAGONISTS; STATISTICS, NONPARAMETRIC; TABLETS, ENTERIC-COATED; THIOPHENES; YOUNG ADULT;

EID: 69949117145     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11315780-000000000-00000     Document Type: Article

References (26)

1. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129 (5): 394-405
2. Algaier I, Jakubowski JA, Asai F, et al. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 2008; 6 (11): 1908-1914
3. Yusuf S, Zhao F, Mehta SR, et al., on behalf of the Clopi-dogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7): 494-502
4. Steinhubl SR, Berger PB, Mann JT III, et al., on behalf of the Clopidogrel for the Reduction of Events During Observation (CREDO) Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-2420
5. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl. 3: 576-99S
6. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine anti-platelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34 (4): 600-607
7. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine pro-drug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008; 36 (7): 1227-1232
8. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007; 35 (7): 1096-1104
9. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153 (1): 66.e9-16
10. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopido-grel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81 (5): 735-741
11. Payne CD, Li YG, Small DS, et al. Increased active meta-bolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Car-diovasc Pharmacol 2007; 50 (5): 555-562
12. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27 (10): 1166-1173
13. Wiviott SD, Antman EM, Winters KJ, et al., for the JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous cor- onary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111 (25): 3366-3373
14. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29 (1): 21-30
15. Wiviott SD, Braunwald E, McCabe CH, et al., on behalf of the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20): 2001-2015
16. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharma-cokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5 (12): 2429-2436
17. Mega JL, Close SL, Wiviott et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119 (19): 2553-2560
18. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (4): 354-362
19. Farid NA, Payne CD, Ernest CS 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008; 48 (1): 53-59
20. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Phar-macol 2000; 129 (7): 1439-1446
21. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21 (2): 169-179
22. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48 (4): 475-484
23. Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008; 24 (8): 2251-2257
24. Data on file, Daiichi Sankyo, Inc. and Eli Lilly and Company, 2007
25. Boldt J, Huttner I, Suttner S, et al. Changes of haemostasis in patients undergoing major abdominal surgery: is there a difference between elderly and younger patients? Br J An-aesth 2001; 87 (3): 435-440
26. Boldt J, Haisch G, Kumle B, et al. Does coagulation differ between elderly and younger patients undergoing cardiac surgery? Intensive Care Med 2002; 28 (4): 466-471